The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).
 
Avyakta Kallam
No Relationships to Disclose
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Celgene; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Mark J. Roschewski
No Relationships to Disclose
 
Elizabeth Lyden
No Relationships to Disclose
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bayer; Celgene; Genentech; Genzyme; Gilead Sciences; Janssen Oncology; Juno Therapeutics; Kite, a Gilead company; Novartis; Pharmacyclics; Portola Pharmaceuticals; Seagen; Spectrum Pharmaceuticals; TG Therapeutics; Verastem
Research Funding - Celgene (Inst); Celgene (Inst); Celgene (Inst); Curis (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); miRagen (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Philip Jay Bierman
No Relationships to Disclose
 
Gregory Bociek
Consulting or Advisory Role - Innate Pharma
 
James O. Armitage
Leadership - Tesaro
Stock and Other Ownership Interests - Tesaro
Consulting or Advisory Role - Ascentage Pharma; Conatus; Lundbeck; Oncology Analytics; Partner Therapeutics; Samus Therapeutics
 
Julie Vose
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Epizyme; Janssen Scientific Affairs; Karyopharm Therapeutics; Kite/Gilead; Legend Biotech; Miltenyi Biotec; Nordic Nanovector; Novartis; Roche; Sandoz; Vaniam Group; Verastem
Consulting or Advisory Role - Bio Connections
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Seagen (Inst)